Laura Sala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura Sala has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Simone Canesi
Department of Veterinary Medicine and Animal Sciences, University of Milan, Lodi, Italy
5 shared publications - Camilla Recordati
Department of Veterinary Medicine and Animal Sciences, University of Milan, Lodi, Italy
3 shared publications - Eugenio Scanziani
Department of Veterinary Medicine and Animal Sciences (DIVAS), University of Milan, Via dell'Università 6, Lodi 26900, Italy; Mouse and Animal Pathology Laboratory (MAPLab), Fondazione Unimi, Viale Ortles 22/4, Milan 20139, Italy
3 shared publications - Giovanna Damia
Laboratory of Preclinical Gynecological Oncology, Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
2 shared publications - Michela Chiappa
Laboratory of Preclinical Gynecological Oncology, Department of Experimental Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
2 shared publications - Robert Fruscio
Department of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy
2 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 15 (1) , 94
Combination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer
- 15 September 2026
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 15 (1) , 94
Open AccessCombination of PARPi and topoisomerase I inhibitors is highly effective in olaparib-resistant ovarian cancer
- Open Access
- 3 September 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism
Epithelial ovarian cancer (EOC) is a highly lethal disease characterized by a high rate of platinum (PT)-resistant recurrence. Dysregulation of transcriptional and alternative splicing (AS) has been suggested as a possible mechanism of PT resistance involving transcriptional cyclin-dependent kinases (CDKs). We report that pharmacological CDK12/CDK13 inhibition (CDK12i) synergistically enhances PT-induced cytotoxicity in a large number of PT-sensitive and PT-resistant EOC models. CDK12i effectively delayed the emergence of PT-resistant recurrences in vitro and in vivo. Acquired resistance to CDK12i enhanced PT sensitivity, revealing a therapeutically exploitable vulnerability to PT. CDK12i strongly reshapes transcriptional elongation and RNA processing, impacting multiple categories of AS, with marked enrichment of transcripts involved in the DNA damage repair (DDR) pathway. We proved that CDK12 interacts with the splicing master regulator SFPQ/p54 nrb complex, driving its distribution in transcriptional condensates. The p54 nrb subunit of the complex is required for the CDK12-SFPQ interaction and to ensure splicing reprogramming and CDK12i-induced cytotoxicity in all the EOC models tested. The use of CT7439, a novel clinical-grade CDK12i, which is now in phase I/II clinical trials, confirmed the therapeutic potential of CDK12i, either as monotherapy or in combination with PT. These findings emphasize that the therapeutic potential of CDK12i extends beyond DDR regulation, encompassing a critical role in RNA processing and AS. This dual impact affects EOC survival and may provide a novel, clinically relevant therapeutic strategy for hard-to-treat PT-resistant patients for whom effective treatment options remain limited.
- 3 September 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Open AccessCDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism
Epithelial ovarian cancer (EOC) is a highly lethal disease characterized by a high rate of platinum (PT)-resistant recurrence. Dysregulation of transcriptional and alternative splicing (AS) has been suggested as a possible mechanism of PT resistance involving transcriptional cyclin-dependent kinases (CDKs). We report that pharmacological CDK12/CDK13 inhibition (CDK12i) synergistically enhances PT-induced cytotoxicity in a large number of PT-sensitive and PT-resistant EOC models. CDK12i effectively delayed the emergence of PT-resistant recurrences in vitro and in vivo. Acquired resistance to CDK12i enhanced PT sensitivity, revealing a therapeutically exploitable vulnerability to PT. CDK12i strongly reshapes transcriptional elongation and RNA processing, impacting multiple categories of AS, with marked enrichment of transcripts involved in the DNA damage repair (DDR) pathway. We proved that CDK12 interacts with the splicing master regulator SFPQ/p54 nrb complex, driving its distribution in transcriptional condensates. The p54 nrb subunit of the complex is required for the CDK12-SFPQ interaction and to ensure splicing reprogramming and CDK12i-induced cytotoxicity in all the EOC models tested. The use of CT7439, a novel clinical-grade CDK12i, which is now in phase I/II clinical trials, confirmed the therapeutic potential of CDK12i, either as monotherapy or in combination with PT. These findings emphasize that the therapeutic potential of CDK12i extends beyond DDR regulation, encompassing a critical role in RNA processing and AS. This dual impact affects EOC survival and may provide a novel, clinically relevant therapeutic strategy for hard-to-treat PT-resistant patients for whom effective treatment options remain limited.
- Open Access
- 28 January 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (3) , 176
Batch-Dependent Hepatobiliary Toxicity of 10 nm Silver Nanoparticles After Single Intravenous Administration in Mice
Silver nanoparticles (AgNPs) are extensively employed for their antimicrobial and biomedical properties, yet concerns persist regarding their potential toxicity. While AgNPs can induce oxidative stress, membrane disruption, and DNA damage, in vivo data remain inconsistent. This study investigated whether batch-to-batch variability in nominally identical AgNPs of 10 nm size contributes to divergent in vivo toxicity outcomes. CD-1 (ICR) mice were intravenously injected with a single 10 mg/kg bw dose of spherical, citrate-coated 10 nm AgNPs from three different batches purchased from the same manufacturer. The mice were euthanized 24 h post-exposure for quantitative silver determination by inductively coupled plasma–mass spectrometry (ICP–MS) and histopathological evaluation of liver, spleen, lungs, kidneys, and brain. Autometallography and immunofluorescence were used to assess silver distribution and cellular localization in the hepatobiliary system. All the batches induced hepatobiliary toxicity, characterized by hepatocellular necrosis and gallbladder wall hemorrhage, of differing severity. The most toxic batches contained higher proportions of smaller AgNPs, suggesting that differences in size distribution influence toxicological outcomes. Silver agglomerates were localized within multiple cell types, indicating internalization and cell-specific cytotoxicity. These findings highlight that minor physicochemical variations affect in vivo results, underscoring the importance of nanoparticle characterization to improve reproducibility in nanotoxicological research.
- 28 January 2026
- Published by MDPI AG in Nanomaterials
- Vol. 16 (3) , 176
Open AccessBatch-Dependent Hepatobiliary Toxicity of 10 nm Silver Nanoparticles After Single Intravenous Administration in Mice
Silver nanoparticles (AgNPs) are extensively employed for their antimicrobial and biomedical properties, yet concerns persist regarding their potential toxicity. While AgNPs can induce oxidative stress, membrane disruption, and DNA damage, in vivo data remain inconsistent. This study investigated whether batch-to-batch variability in nominally identical AgNPs of 10 nm size contributes to divergent in vivo toxicity outcomes. CD-1 (ICR) mice were intravenously injected with a single 10 mg/kg bw dose of spherical, citrate-coated 10 nm AgNPs from three different batches purchased from the same manufacturer. The mice were euthanized 24 h post-exposure for quantitative silver determination by inductively coupled plasma–mass spectrometry (ICP–MS) and histopathological evaluation of liver, spleen, lungs, kidneys, and brain. Autometallography and immunofluorescence were used to assess silver distribution and cellular localization in the hepatobiliary system. All the batches induced hepatobiliary toxicity, characterized by hepatocellular necrosis and gallbladder wall hemorrhage, of differing severity. The most toxic batches contained higher proportions of smaller AgNPs, suggesting that differences in size distribution influence toxicological outcomes. Silver agglomerates were localized within multiple cell types, indicating internalization and cell-specific cytotoxicity. These findings highlight that minor physicochemical variations affect in vivo results, underscoring the importance of nanoparticle characterization to improve reproducibility in nanotoxicological research.
- Open Access
- 4 September 2025
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 245, 106672
Application of computer vision for automated detection of different lesions in pig lungs: An exploratory study
- 4 September 2025
- Published by Elsevier in Preventive Veterinary Medicine
- Vol. 245, 106672
Open AccessApplication of computer vision for automated detection of different lesions in pig lungs: An exploratory study
- Open Access
- 14 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5708
Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas
Platinum resistance represents an urgent medical need in the management of ovarian cancer. The activity of the combinations of onvansertib, an inhibitor of polo-like kinase 1, with gemcitabine or carboplatin was tested using patient-derived xenografts of high-grade serous ovarian carcinoma resistant to cisplatin (DDP). Two PDX models were selected from our xenobank: one with acquired resistance to DDP (#266R) and the other (#315) with intrinsic DDP resistance. Tumor-bearing mice were randomized to receive vehicle, single onvansertib, gemcitabine and carboplatin, and their combinations. Onvansertib/gemcitabine and onvansertib/carboplatin combinations were well tolerated. In the #266R model, single drug treatments were completely inactive, while the combinations of onvansertib/gemcitabine and onvansertib/carboplatin resulted in a significant increase in survival compared to controls and single drugs (p < 0.001 versus control, onvansertib, gemcitabine and carboplatin). Similar efficacy was observed in the s.c. #315 PDX model; indeed, onvansertib and carboplatin monotherapies were inactive, gemcitabine monotherapy was marginally active, while both combinations were highly active. The molecular mechanism underlying the efficacy of the combinations suggests a higher induction of DNA damage which seems plausible considering that, in both cases, gemcitabine and carboplatin, respectively, interfere with DNA metabolism and induce alkylation damage. The results suggest that the combinations of onvansertib/gemcitabine and onvansertib/carboplatin are safe and were shown to be of therapeutic value in the platinum-resistant setting of ovarian carcinoma, strongly supporting their clinical translatability.
- 14 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5708
Open AccessOnvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas
Platinum resistance represents an urgent medical need in the management of ovarian cancer. The activity of the combinations of onvansertib, an inhibitor of polo-like kinase 1, with gemcitabine or carboplatin was tested using patient-derived xenografts of high-grade serous ovarian carcinoma resistant to cisplatin (DDP). Two PDX models were selected from our xenobank: one with acquired resistance to DDP (#266R) and the other (#315) with intrinsic DDP resistance. Tumor-bearing mice were randomized to receive vehicle, single onvansertib, gemcitabine and carboplatin, and their combinations. Onvansertib/gemcitabine and onvansertib/carboplatin combinations were well tolerated. In the #266R model, single drug treatments were completely inactive, while the combinations of onvansertib/gemcitabine and onvansertib/carboplatin resulted in a significant increase in survival compared to controls and single drugs (p < 0.001 versus control, onvansertib, gemcitabine and carboplatin). Similar efficacy was observed in the s.c. #315 PDX model; indeed, onvansertib and carboplatin monotherapies were inactive, gemcitabine monotherapy was marginally active, while both combinations were highly active. The molecular mechanism underlying the efficacy of the combinations suggests a higher induction of DNA damage which seems plausible considering that, in both cases, gemcitabine and carboplatin, respectively, interfere with DNA metabolism and induce alkylation damage. The results suggest that the combinations of onvansertib/gemcitabine and onvansertib/carboplatin are safe and were shown to be of therapeutic value in the platinum-resistant setting of ovarian carcinoma, strongly supporting their clinical translatability.
- 29 January 2025
- Published by SAGE Publications in Veterinary Pathology
- Vol. 62 (3) , 382-396
Sex-dependent modulation of caerulein-induced acute pancreatitis in C57BL/6J mice
Acute pancreatitis (AP) is a life-threatening condition, with a higher mortality rate in men than women and in which estrogens might play a protective role. This study aimed to investigate sex-dependent differences in a mouse model of caerulein-induced AP. Thirty-six C57BL/6J mice (19 females and 17 males) were treated intraperitoneally with phosphate-buffered saline or caerulein, and sacrificed 12 hours, 2 days, or 7 days after the last injection. Blood was collected for amylase, lipase, and glucose determination. Severity and extent of inflammation, apoptosis, and acinar to ductal metaplasia (ADM) in pancreatic tissue were scored histologically and total macrophages, major histocompatibility complex (MHC)-II+ cells, M2 macrophages, T and B cells, neutrophils, apoptosis, and ADM were marked immunohistochemically and quantified by digital image analysis. Serum amylase had a peak at 12 hours, without differences between the sexes. In females, pancreatitis reached a peak at 12 hours with a fast recovery while, in males, the peak was delayed to day 2 with residual apoptosis still present. Macrophages were the main inflammatory cell population, followed by T cells, B cells and neutrophils, without differences between sexes. In males, CD206+ cells and apoptosis were higher at both days 2 and 7, and cytokeratin-19+ (CK19+) ADM was higher at day 7 compared with females. The results of this study revealed a faster onset and resolution of caerulein-induced AP in female mice compared with male mice, supporting a sex-dependent modulation of acute pancreatitis.
- 29 January 2025
- Published by SAGE Publications in Veterinary Pathology
- Vol. 62 (3) , 382-396
Sex-dependent modulation of caerulein-induced acute pancreatitis in C57BL/6J mice
Acute pancreatitis (AP) is a life-threatening condition, with a higher mortality rate in men than women and in which estrogens might play a protective role. This study aimed to investigate sex-dependent differences in a mouse model of caerulein-induced AP. Thirty-six C57BL/6J mice (19 females and 17 males) were treated intraperitoneally with phosphate-buffered saline or caerulein, and sacrificed 12 hours, 2 days, or 7 days after the last injection. Blood was collected for amylase, lipase, and glucose determination. Severity and extent of inflammation, apoptosis, and acinar to ductal metaplasia (ADM) in pancreatic tissue were scored histologically and total macrophages, major histocompatibility complex (MHC)-II+ cells, M2 macrophages, T and B cells, neutrophils, apoptosis, and ADM were marked immunohistochemically and quantified by digital image analysis. Serum amylase had a peak at 12 hours, without differences between the sexes. In females, pancreatitis reached a peak at 12 hours with a fast recovery while, in males, the peak was delayed to day 2 with residual apoptosis still present. Macrophages were the main inflammatory cell population, followed by T cells, B cells and neutrophils, without differences between sexes. In males, CD206+ cells and apoptosis were higher at both days 2 and 7, and cytokeratin-19+ (CK19+) ADM was higher at day 7 compared with females. The results of this study revealed a faster onset and resolution of caerulein-induced AP in female mice compared with male mice, supporting a sex-dependent modulation of acute pancreatitis.
- Open Access
- 28 September 2024
- Published by Springer Nature in Veterinary Research Communications
- Vol. 48 (6) , 4021-4028
Mammary carcinoma in a male cat following long-term medroxyprogesterone acetate treatment: case report and review of the literature
In male cats, as in men, mammary carcinomas are rarely reported. However, like in females, hormonal therapy is a significant risk factor. This study reports the case of an 11-year-old male cat with multiple mammary tumours and a history of long-term medroxyprogesterone acetate therapy for the suppression of sexual behaviour, along with a brief review of the literature. Complete surgical removal of the right mammary chain and the ipsilateral inguinal lymph nodes was performed, and all tissues were submitted for histology. Histological examination revealed the presence of a tumour in the third and fourth mammary glands, consisting of neoplastic cells arranged in various structures, including tubulopapillary and tubular structures, sometimes cystically dilated, and solid areas. The inguinal lymph nodes were also involved. The morphology was consistent with a diagnosis of mammary carcinoma, tubulopapillary type, with nodal metastases. Immunohistochemistry revealed that tumour cells were positive for cytokeratin (clones AE1/AE3), while stromal cells were positive for vimentin (clone V9). The proliferation marker Ki-67, evaluated on both the primary tumour and the nodal metastases, was strongly expressed in the nuclei of neoplastic cells, with a Ki-67 proliferation index of 8.9% and 20% for the primary tumour and the metastases, respectively. This case highlights the importance of considering the possibility of malignant mammary tumours not only in female but also in male cats with a history of long-term hormonal treatment for suppression of sexual behaviour.
- 28 September 2024
- Published by Springer Nature in Veterinary Research Communications
- Vol. 48 (6) , 4021-4028
Open AccessMammary carcinoma in a male cat following long-term medroxyprogesterone acetate treatment: case report and review of the literature
In male cats, as in men, mammary carcinomas are rarely reported. However, like in females, hormonal therapy is a significant risk factor. This study reports the case of an 11-year-old male cat with multiple mammary tumours and a history of long-term medroxyprogesterone acetate therapy for the suppression of sexual behaviour, along with a brief review of the literature. Complete surgical removal of the right mammary chain and the ipsilateral inguinal lymph nodes was performed, and all tissues were submitted for histology. Histological examination revealed the presence of a tumour in the third and fourth mammary glands, consisting of neoplastic cells arranged in various structures, including tubulopapillary and tubular structures, sometimes cystically dilated, and solid areas. The inguinal lymph nodes were also involved. The morphology was consistent with a diagnosis of mammary carcinoma, tubulopapillary type, with nodal metastases. Immunohistochemistry revealed that tumour cells were positive for cytokeratin (clones AE1/AE3), while stromal cells were positive for vimentin (clone V9). The proliferation marker Ki-67, evaluated on both the primary tumour and the nodal metastases, was strongly expressed in the nuclei of neoplastic cells, with a Ki-67 proliferation index of 8.9% and 20% for the primary tumour and the metastases, respectively. This case highlights the importance of considering the possibility of malignant mammary tumours not only in female but also in male cats with a history of long-term hormonal treatment for suppression of sexual behaviour.